-
FDA approves new drug Rocklatan to reduce intra-eye pressure in open-angle glaucoma or high-eye pressure patients
Time of Update: 2020-06-10
recent, the United States The FDA (http:// approved the new drug (http:// Rocklatan to reduce intra-eye pressure (IOP) in patients with open-angle glaucoma or hyper-eye pressure Rocklatan Ro
-
FDA accepts application for application for treatment of advanced renal cell carcinoma by Bavencio (avelumab) and Inlyta (Axitinib)
Time of Update: 2020-06-10
renal cell carcinoma is the most common type of kidney cancer, accounting for about 70% of patients with kidney cancer, accounting for 2% to 3% of all types of cancer patients in adults Although the
-
FDA grants NeuroRx drug NRX-101 breakthrough therapy certification
Time of Update: 2020-06-10
recently, NeuroRx (http:// announced that its drug (http:// NRX-101 has been certified by the U.S FDA (http:// NRX-101 is primarily used to treat patients with severe bipolar depression wit
-
FDA approves Mercay Heavy Anti-PD-1 Therapy Keytruda For Advanced/Metastatic Non-Small Cell Lung Cancer
Time of Update: 2020-06-10
today, The FDA's (http:// announced approval of the heavy-duty anti-PD-1 therapy, developed by the http:// Company , , as a single-drug therapy for PD-L1-positive late-stage/metastatic non-small
-
New drug application for the first three CSF1R inhibitors pexidartinib is eligible for FDA Priority Review
Time of Update: 2020-06-10
recently, Daiichi Sankyo company (http:// announced that its application for the of New Drug (http:// (NDA) for the CSF1R inhibitor pexitinib has been accepted by the u.S FDA (http:// , and
-
U.S. FDA Grants Phosphate Inositol-3-Kinase (PI3K) Inhibitor umbralisib (TGR-1202) Orphan Drug Qualification
Time of Update: 2020-06-10
recently, TG (http:// announced that the U.S Food and Drug (http:// Administration ( FDA (http:// ) has granted the phosphate inositol-3-kinase (PI3K) inhibitor umbralisib (PiGR-1202) orphan
-
Novartis CAR-T cell therapy Kymriah is approved by Health Canada for 2 B-cell malignancies
Time of Update: 2020-06-10
, the CAR-T cell therapy Kymriah (CTL019), developed by Swiss Pharmaceutical (http:// giant Novartis, has been approved by Health Canada for 2 Types of B-cell malignancies : (1) B-cell acute lymp
-
FDA approves ADMA's application for listing of intravenous immunoglobulin 10% formulation Asceniv
Time of Update: 2020-06-10
PIDD refers to the loss of some function or disorder of the body's immune system due to genetic causes Given the loss of part of the immune system, people with PIDD are more susceptible to infection
-
European Commission approves Delstrigo and Pifeltro for treatment of HIV-1 infection
Time of Update: 2020-06-10
recently, the us Pharmaceutical (http:// giant Merck and Co announced that the European Commission (EC) has approved Delstrigo and Pifeltro to treat HIV-1 infections the company http:// has p
-
Tarlige's four-spec tablet has been approved in Japan for treatment of peripheral neuropathic pain
Time of Update: 2020-06-10
recently, Daiichi Sankyo, a Japanese pharmaceutical company, announced that 2.5mg, 5mg, 10mg and 15mg tablets of the mirolige (mirogabalin besylate) have been approved in Japan for the treatment of
-
NMPA approves Gilead's new hepatitis B drug phosphatinofa (JXHL1700186) for the treatment of chronic hepatitis B
Time of Update: 2020-06-10
recently, Gilead hepatitis B new drug (http:// phosphatinofa tablets (TAF) of the new drug application (JXHL1700186) was approved by the National Drug (http:// Administration (NMPA) for the tr
-
FDA approves Darzalex's new method of administration
Time of Update: 2020-06-10
recently, Jansen announced the FDA (http:// approve daratumab's new administration, the first dose (16 mg/kg) can be completed in two consecutive days of intravenous infusion, professional medic
-
FDA approves for launch of another psoriasis treatment
Time of Update: 2020-06-10
psoriasis is an inflammatory disease In the United States, there are about 7.5 million psoriasis patients, 80 percent of whom suffer from plaque psoriasis recently, the U.S FDA (http:// approved
-
Navuliu monoantigen (Odivo) joint Ipitaph monoantigen has been approved by the European Commission for first-line treatment for patients with renal cell carcinoma
Time of Update: 2020-06-10
recently, Baishi MeishiBao announced that Navuliyu monoantigen (Odivo) 3 mg/kg joint Ipitano 1 mg/kg ("low dose") program has been approved by the European Commission for the first-line treatment of
-
NMPA approves new HIV compound drug Descovy for treatment of HIV-1 infection in adults and adolescents
Time of Update: 2020-06-10
recently, gilead, the giant of Pharmaceutical (http:// announced that China's National Drug (http:// Regulatory Authority (NMPA) has approved the of the new drug (http:// of HIV complex /Pr
-
Ono Launches Demser250mg Capsules in Japan for Treatment of Patients with Chromoblastoma
Time of Update: 2020-06-10
chromosomal cell tumor (PC) is a neuroendocrine tumor that originates in the adrenal myelin or the peripheral nerve section of the adrenal gland, with an estimated 2,920 patients in Japan recently,
-
Legendary Bio and Johnson and Johnson co-developed multi-meeloma drug JNJ-68284528 to be recognized as A preferred drug by EMA
Time of Update: 2020-06-10
recently, Kingsley Biotech Limited Company (http:// announced that its subsidiary Legendary Bio and Johnson Pharmaceuticals (http:// subsidiary, Janssen Pharmaceuticals, have jointly developed
-
FDA approves janson Balversa (erdafitinib) to be marketed for treatment in adult patients with advanced or metastatic bladder cancer
Time of Update: 2020-06-10
bladder cancer is the sixth most common cancer in the United States, with the most common bladder cancer being urinary skin cancer Bladder cancer is usually associated with genetic mutations in the
-
Gene Tek's anti-PD-L1 mono-antitherapy Tecentriq (atezolizumab) gets FDA approval
Time of Update: 2020-06-10
recently, Roche's Genentech company, ,http:// announced that its anti-PD-L1 mono-antitherapy Tecentriq (atezolizumab) had been approved by the FDA (http:// , and that chemotherapy had become a f
-
FDA approves Sunosi (solriamfetol) to treat over-day drowsiness associated with OSA syndrome
Time of Update: 2020-06-10
today, the FDA (http:// announced the approval of Jazz Pharmaceuticals 's (http:// to treat daytime excessive drowsiness associated with narcolepsy or obstructive sleep apnea (OSA) syndrome Ab
